510(k) Report

510(k) · Cleared

Recalled · Class II · 2015

Nxstage System One with Nxview

K133547510(k) TraditionalCleared Mar 3, 2014104-day reviewClass II21 CFR 876.5860Recalls 2

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Nxstage Medical, Inc. · KDI Dialyzer, High Permeability With Or Without Sealed Dialysate System

Cleared on Mar 3, 2014 as substantially equivalent to K122051 (Nxstage Medical, Inc., 2013) and 1 other predicate after a 104-day review. Its family tree reaches back 2 generations to 1994. 1 later device descends from it. It has been recalled 2 times.

Decided
Mar 3, 2014
Review
104 days
Class
Class II
Product code
KDI
Recalls
2
Predicates
2

Its longest line of descent runs back 2 generations to K921456 (1994). 5 ancestors in all. 1 later device descends from it, 1 citing it directly.

Other ancestors, by generationDescendants, by generation 1 generation back: 1 other ancestor2 generations back: 2 other ancestors 1 generation forward: 1 descendant K040074 · Oneview Interface · Nxstage Medical, Inc. · 2004K921456 · Fresenius 3008/FDS-08 Dialysate Delivery System · Fresenius USA, Inc. · 1994 · recalled0
  1. Root · 2 generations backK921456 Fresenius 3008/FDS-08 Dialysate Delivery SystemFresenius USA, Inc. · 1994 · Recalled
  2. 1 generation backK040074 Oneview InterfaceNxstage Medical, Inc. · 2004
  3. This deviceK133547 Nxstage System One with NxviewNxstage Medical, Inc. · 2014
  4. Descendant · cites it directly · 0 of its ownK252377 NxStage System One with NxViewFresenius Medical Care Renal Therapies Group, LLC · 2026

Most influential descendants

Showing 1 of 1 · See all
  • K252377NxStage System One with NxViewFresenius Medical Care Renal Therapies Group, LLC · 2026 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K921456Fresenius 3008/FDS-08 Dialysate Delivery SystemFresenius USA, Inc.19943
−1K040074Oneview InterfaceNxstage Medical, Inc.2004—
0 (this device)K133547Nxstage System One with NxviewNxstage Medical, Inc.2014—
+1K252377NxStage System One with NxViewFresenius Medical Care Renal Therapies Group, LLC2026—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200210
201010
201310

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202610
FIG. 1 — Lineage of K133547, 1994–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KDI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KDI device

  1. #1 K243874 FX CorAL 60 (F00012969); FX CorAL 80…score 18.2 · 12 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K122051Nxstage System One
Summary page 2
…amental technology as the predicate NxStage System One. The NxStage System One with NxView has been compared to the legally marketed predicate devices as cleared through K122051 (April 23, 2013) and K040074 (April 8, 2004) and was found to be substantially equivalent. E. Device Description/Indications for…
Nxstage Medical, Inc.20131
*K040074Oneview Interface
Summary page 2
…dicate NxStage System One. The NxStage System One with NxView has been compared to the legally marketed predicate devices as cleared through K122051 (April 23, 2013) and K040074 (April 8, 2004) and was found to be substantially equivalent. E. Device Description/Indications for Use: The NxStage System One…
Nxstage Medical, Inc.2004—
†K043436Nxstage Dialysate Preparation Module, Model NX0269Nxstage Medical, Inc.2005—
†K060236MW-1000 Iontophoretic Drug Delivery ElectrodeIomed, Inc.2006—
†K020919Atricure Bipolar System, Models ASU1, ASU2, ASU3, LHP1, LHP2, RHP1AtriCure, Inc.2002—
†K111174Nxstage Pureflow SLNxstage Medical, Inc.20119

Also cleared against K122051: 1 other device →

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K252377NxStage System One with NxViewFresenius Medical Care Renal Therapies Group, LLC20260

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Oct 29, 2015Class IIZ-0326-2016Software Design ChangeUltrafiltration (UF) Volume software error inaccurate fluid removal
Oct 29, 2015Class IIZ-0327-2016Software Design ChangeUltrafiltration (UF) Volume software error inaccurate fluid removal

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 20 years and passes through 2 companies; a new generation was cleared every 10.0 years on median.
  • 2 of the 5 ancestors have a recall of any class.
  • Of its descendants, K252377 (Fresenius Medical Care Renal Therapies Group, LLC, 2026) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K122051.

How does its category compare?

All KDI devices

KDI Dialyzer, High Permeability With Or Without Sealed Dialysate System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · KDI

9in 2025

2007: 112008: 62009: 42010: 92011: 52012: 62013: 112014: 82015: 52016: 52017: 82018: 22019: 42020: 92021: 22022: 72023: 72024: 72025: 92026 (partial year): 6
2007high 11 (2007) · low 2 (2018)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KDI

199in 2025

2007: 91 days median2008: 148 days median2009: 236 days median2010: 186 days median2011: 85 days median2012: 153 days median2013: 247 days median2014: 164 days median2015: 69 days median2016: 230 days median2017: 188 days median2019: 263 days median2020: 266 days median2022: 259 days median2023: 157 days median2024: 235 days median2025: 199 days median2026 (partial year): 154 days median
2007high 266 (2020) · low 69 (2015)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KDI

2in 2025

2007: 42009: 32010: 12011: 42012: 12013: 22014: 32015: 52016: 42017: 12018: 12019: 62021: 22022: 172023: 8, 8 Class I2024: 4, 2 Class I2025: 22026 (partial year): 2
2007high 17 (2022) · low 0 (2008)2026

Class I (10 since 2007) Class II/III not classified

Adverse event reports per year · KDI

2,786in 2025

2007: 9162008: 1,0422009: 5222010: 8232011: 2,2702012: 1,7652013: 2,3602014: 6,1542015: 4,1822016: 7662017: 9632018: 1,7162019: 1,5872020: 1,6332021: 1,9442022: 2,1802023: 2,6922024: 2,4412025: 2,786
2007high 6,154 (2014) · low 522 (2009)2025

MAUDE reports naming product code KDI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200711914916
2008614801,042
200942363522
201091861823
201158542,270
2012615311,765
20131124722,360
2014816436,154
201556954,182
201652304766
201781881963
20182—11,716
2019426361,587
2020926601,633
20212—21,944
20227259172,180
202371578 (8)2,692
202472354 (2)2,441
2025919922,786
202661542—

What is it indicated for?

NxStage System One: The NxStage System One is indicated for the treatment of acute and chronic renal failure, or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration, in an acute or chronic care facility. The NxStage System One is also indicated for Therapeutic Plasma Exchange in a clinical environment. All treatments must be administered under physician's prescription, and must be observed by a trained and qualified person…

Read the full statement (114 words)

NxStage System One:

The NxStage System One is indicated for the treatment of acute and chronic renal failure, or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration, in an acute or chronic care facility.

The NxStage System One is also indicated for Therapeutic Plasma Exchange in a clinical environment.

All treatments must be administered under physician's prescription, and must be observed by a trained and qualified person, considered to be competent in the use of this device by the prescribing physician.

NxView:

NxView is a computer-based touch screen user interface that provides on-line instructions for use, summarized system information and remote access.

NxView is contraindicated as the sole method of monitoring a patient during treatment.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K133547: Nxstage System One with Nxview.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K133547

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026